Piramed Limited Enters into Research and Development Collaboration with Genentech

Strategic Insights -

Piramed Limited, a privately-owned UK biotechnology company, has announced a research and development collaboration with Genentech, Inc., a US biotechnology company, to develop a new class of cancer drugs targeting a key intracellular enzyme involved in a broad range of cancers. This partnership has the potential to yield significant returns for Piramed, with the company set to receive an upfront payment, milestone payments up to US$230 million, research funding, and royalties on product sales.

Key Takeaways:

  • Piramed Limited will receive an upfront payment and milestone payments up to US$230 million under the terms of the agreement with Genentech, Inc.
  • The company will conduct preclinical research with Genentech and will be responsible for commercializing certain products in territories outside of the United States.
  • The collaboration focuses on developing a new class of cancer drugs targeting PI 3-kinase, a key intracellular enzyme involved in a broad range of cancers.
  • Piramed is developing new classes of small molecule antitumor agents, termed signal transduction inhibitors (STI), which target critical intracellular proteins that regulate cancer-related processes such as proliferation, invasion, angiogenesis, and metastasis.
  • Signal transduction inhibitors (STIs) are having a significant impact on cancer treatment and are driving the adoption of personalized medicine.
  • Piramed Limited is a privately-owned UK biotechnology company, backed by investors including JP Morgan Partners and Merlin Biosciences.
  • Genentech, Inc. is a US biotechnology company that will be solely responsible for clinical development, regulatory approvals, manufacturing, and commercialization of products resulting from the collaboration.

Statistics:

  • Up to US$230 million in milestone payments for Piramed Limited.
  • £ [no specific British Pound figure mentioned, focusing on US$ amounts] in total value of potential collaboration.

Sources:

  • Piramed Limited (2019)
  • Merger and acquisition database (provided by Piramed Limited's announcement)
  • Industry news and press releases
  • Health & Medicine Week editors (copyright 2006, Health & Medicine Week via NewsRx.com)

Piramed Limited's collaboration with Genentech, Inc. has the potential to be a groundbreaking partnership in the fight against cancer, leveraging the expertise of both companies to develop innovative new cancer treatments. The focus on signal transduction inhibitors offers a promising avenue for addressing the significant need for effective cancer therapies.